Skip to content
HowShorted

MADRIGAL PHARMACEUTICALS, INC. short interest in 2023

In 2023, MADRIGAL PHARMACEUTICALS, INC.'s disclosed short interest ran from 5.70% of shares outstanding on 13 Jan 2023 to 16.48% on 29 Dec 2023, a change of +10.78 percentage points. The year's high was 18.47% on 31 Oct 2023 and its low 5.51% on 15 Feb 2023, averaging 10.65% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.96 days on 29 Dec 2023. Full history: MADRIGAL PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for MADRIGAL PHARMACEUTICALS, INC. in 2023

2023 in figures

Start of year
5.70% (13 Jan 2023)
End of year
16.48% (29 Dec 2023)
Change
+10.78 pp
High
18.47% (31 Oct 2023)
Low
5.51% (15 Feb 2023)
Average
10.65%
Highest days to cover
10.96 (29 Dec 2023)
SEC filings marked
8

Every report in 2023

MADRIGAL PHARMACEUTICALS, INC. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20235.70%2.30
31 Jan 20235.52%3.06
15 Feb 20235.51%2.88
28 Feb 20236.02%1.9010-K filed, results (8-K)
15 Mar 20237.01%2.60
31 Mar 20237.26%2.81
14 Apr 20238.67%5.62
28 Apr 20238.10%3.45
15 May 20236.91%3.6410-Q filed, results (8-K)
31 May 20237.94%4.43
15 Jun 20238.77%6.26
30 Jun 20239.61%2.57
14 Jul 202310.31%10.25
31 Jul 202310.01%7.64
15 Aug 20239.79%5.7110-Q filed, results (8-K)
31 Aug 202310.62%10.11
15 Sep 202311.54%4.19
29 Sep 202314.32%5.22
13 Oct 202316.30%5.29
31 Oct 202318.47%8.73
15 Nov 202317.50%7.4910-Q filed, results (8-K)
30 Nov 202317.60%10.16
15 Dec 202315.55%6.45
29 Dec 202316.48%10.96

See also: MADRIGAL PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.